Shares of US generic drugmaker Mylan Laboratories jumped 5.3% to $20.40 on October 4, overshooting the firm's 52-week high on the news that final clearance from the US Food and Drug Administration to sell a copycat version of drug giant Pfizer's blood pressure agent Norvasc (amlodipine besylate) has been granted.
No comments:
Post a Comment